Abstract:Effective, non-addictive therapeutics for chronic pain remain a critical need. While there are several potential therapeutics that stimulate anti-inflammatory mechanisms to restore homeostasis in the spinal dorsal horn microenvironment, the effectiveness of drugs for neuropathic pain are still inadequate. The convergence of increasing knowledge about the multi-factorial mechanisms underlying neuropathic pain and the mechanisms of drug action from preclinical studies are providing the ability to create pharmaceuticals with better clinical effectiveness. By targeting and activating the peroxisome proliferator-activated receptor gamma subunit (PPARγ), numerous preclinical studies report pleiotropic effects of thiazolidinediones (TDZ) beyond their intended use of increasing insulin, including their anti-inflammatory, renal, cardioprotective, and oncopreventative effects. Several studies find TDZs reduce pain-related behavioral symptoms, including ongoing secondary hypersensitivity driven by central sensitization. Previous studies find increased PPARγ in the spinal cord and brain regions innervated by incoming afferent nerve endings after the induction of neuropathic pain models. PPARγ agonist treatment provides an effective reduction in pain-related behaviors, including anxiety. Data further suggest that improved brain mitochondrial bioenergetics after PPARγ agonist treatment is a key mechanism for reducing hypersensitivity. This review emphasizes two points relevant for the development of better chronic pain therapies. First, employing neuropathic pain models with chronic duration is critical since they can encompass the continuum of molecular and brain circuitry alterations arising over time when pain persists, providing greater relevance to clinical pain syndromes. Assisting in that effort are preclinical models of chronic trigeminal pain syndromes. Secondly, considering the access to nerve and brain neurons and glia across the blood-brain barrier is important. While many therapies have low brain penetrance, a PPARγ agonist with better brain penetrance, ELB00824, has been developed. Purposeful design and recent comparative testing indicate that ELB00824 is extraordinarily efficient and efficacious. ELB00824 provides greatly improved attenuation of pain-related behaviors, including mechanical hypersensitivity, anxiety, and depression in our chronic trigeminal nerve injury models. Physiochemical properties allowing significant brain access and toxicity testing are discussed.

Intrathecal delivery of a palmitoylated peptide targeting Y382-384 within the P2X7 receptor alleviates neuropathic pain

P2X7-related modulation of pathological nociception in rats

Targeting 5-HT2A receptors and Kv7 channels in PFC to attenuate chronic neuropathic pain in rats using a spared nerve injury model

A Synthetic Peptide Exerts Nontolerance-Forming Antihyperalgesic and Antidepressant Effects in Mice

Pharmacologically Inhibiting Glur2 Internalization Alleviates Neuropathic Pain

Axotomy-Induced Up-Regulation of Tumor Necrosis Factor-Alpha in the Dorsal Root Ganglia

Intrathecal Infusion of Pyrrolidine Dithiocarbamate for the Prevention and Reversal of Neuropathic Pain in Rats Using a Sciatic Chronic Constriction Injury Model.

Modulation of thalamocingulate nociceptive transmission and glutamate secretion by targeting P2X7 receptor

The Effect of Nr2b Subunit Palmitoylation at the Spinal Level after Chronic Dorsal Root Ganglia Compression in Rats

A Synthetic Peptide Disturbing GluN2A/SHP1 Interaction in Dorsal Root Ganglion Attenuated Pathological Pain

Involvement of Microglial P2X7 Receptors and Downstream Signaling Pathways in Long-Term Potentiation of Spinal Nociceptive Responses

Intrathecal administration of NTS1 agonists reverses nociceptive behaviors in a rat model of neuropathic pain

P2X7 Receptor of Microglia Mediates Neuropathic pain by Regulating Autophagy After Chronic-Constriction Injury

Attenuating Phosphorylation of P38 MAPK in the Activated Microglia: A New Mechanism for Intrathecal Lidocaine Reversing Tactile Allodynia Following Chronic Constriction Injury in Rats

A Synthetic Cell-Penetrating Peptide Antagonizing Trka Function Suppresses Neuropathic Pain in Mice

P2Y12 regulates microglia activation and excitatory synaptic transmission in spinal lamina II neurons during neuropathic pain in rodents

Silencing P2X7R Alleviates Diabetic Neuropathic Pain Involving TRPV1 Via PKCε/P38MAPK/NF-κB Signaling Pathway in Rats.

Intrathecal Administration of Cyclic AMP Response Element-Binding Protein-Antisense Oligonucleotide Attenuates Neuropathic Pain after Peripheral Nerve Injury and Decreases the Expression of N-methyl-D-aspartic Receptors in Mice.

Enduring Reversal of Neuropathic Pain by a Single Intrathecal Injection of Adenosine 2A Receptor Agonists: A Novel Therapy for Neuropathic Pain

Building and Testing PPARγ Therapeutic ELB00824 with an Improved Therapeutic Window for Neuropathic Pain

P2X7R in periaqueductal gray matter participates in nociception modulation of chronic neuropathic pain